A Phase 1 Trial of IO-202, An Antagonist Antibody Targeting Myeloid Checkpoint LILRB4 (ILT3), in Adult Patients with Advanced Relapsed or Refractory Solid Tumors

Written By Lara Wilson

Aung Naing, MD, et al. Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting & Pre-Conference Programs, Boston. November 8–12, 2022

Lara Wilson
Previous

First-In-Human Phase 1 Trial of IO-108, an Antagonist Antibody Targeting LILRB2 (ILT4) as Monotherapy and in Combination with Pembrolizumab in Advanced Solid Tumors: Dose Escalation Data

Next

Antagonistic Antibodies Targeting LAIR1 Enhance T Lymphocyte Activation and Promote Inflammatory Phenotypes in Myeloid Cells